RSV Prevention Tied to Lower Infant Acute Care Use - Scorecard - MDSpire
Advertisement
RSV Prevention Tied to Lower Infant Acute Care Use
Data suggest fewer respiratory syncytial virus–associated hospitalizations and emergency department visits among the youngest infants during the second season of routine prevention product use.
Clinical Scorecard: RSV Prevention Tied to Lower Infant Acute Care Use
At a Glance
Category
Detail
Condition
Respiratory Syncytial Virus (RSV)
Key Mechanisms
Use of nirsevimab and maternal RSV vaccination
Target Population
Infants aged 7 months or younger
Care Setting
Emergency departments and hospitals
Key Highlights
43% relative decrease in RSV-associated hospitalizations and ED visits among infants aged 7 months or younger during the second year of nirsevimab use.
Estimated effectiveness of nirsevimab is between 77% to 90%.
Population-level impact observed with increased immunization coverage in the second season.
Median age of RSV cases increased from 9 months to 12 months over the study period.
Clesrovimab, a new monoclonal antibody, offers an alternative prevention strategy.
Guideline-Based Recommendations
Diagnosis
Use International Statistical Classification of Diseases and Related Health Problems, Tenth Revision codes for RSV-related diagnoses.
Management
Nirsevimab recommended for infants at increased risk for severe RSV disease.
Monitoring & Follow-up
Track hospitalization and emergency department visit rates for RSV.
Risks
Potential misclassification due to reliance on diagnosis codes rather than laboratory confirmation.
Patient & Prescribing Data
Infants born from October 2023 to March 2024, with 39% immunization coverage.
Clesrovimab approved in June 2025, providing a long-acting alternative.
Clinical Best Practices
Evaluate the need for specific recommendations for Native Hawaiian or Other Pacific Islander children.
Consider population-level impacts when assessing RSV prevention strategies.
